Neocleous Vassos, Passalaris Tina, Spanou Elena, Kitsios Petros, Skordis Nicos, Deltas C Constantinou
Cyprus Institute of Neurology and Genetics, Nicosia, Cyprus.
Genet Test. 2004 Summer;8(2):163-8. doi: 10.1089/gte.2004.8.163.
Germ-line mutations of the RET proto-oncogene cause three different cancer syndromes: multiple endocrine neoplasia type 2A (MEN2A), multiple endocrine neoplasia type 2B, and familial medullary thyroid carcinoma (FMTC). The objective of the present study was the clinical and molecular characterization of the first two Greek Cypriot families diagnosed with MEN2A and FMTC. The clinical diagnosis of the probands was based on clinical presentation and supported with laboratory findings (calcitonin and carcinoembryonic antigen tumor marker levels). We screened the RET gene by direct DNA sequencing of exons 10, 11, and 16 using genomic DNA as templates. After identification of the mutation, we also developed the amplification refractory mutation system (ARMS) as an alternative method to direct sequencing for genetic diagnosis of 22 additional individuals from both families. We identified the germ-line missense mutation T --> C of codon 618 of exon 10 (C618R) in the probands of both families. By using ARMS, two members of the MEN2A family and five members of the FMTC family were also found positive for the C618R mutation. These are the first seemingly unrelated families in Cyprus investigated clinically and molecularly in detail and shown to transmit this common RET proto-oncogene mutation.
RET原癌基因的种系突变会引发三种不同的癌症综合征:2A型多发性内分泌腺瘤病(MEN2A)、2B型多发性内分泌腺瘤病以及家族性甲状腺髓样癌(FMTC)。本研究的目的是对塞浦路斯希腊族中最先确诊为MEN2A和FMTC的两个家族进行临床和分子特征分析。先证者的临床诊断基于临床表现,并得到实验室检查结果(降钙素和癌胚抗原肿瘤标志物水平)的支持。我们以基因组DNA为模板,通过对第10、11和16外显子进行直接DNA测序来筛查RET基因。在确定突变后,我们还开发了扩增阻滞突变系统(ARMS),作为对这两个家族另外22名个体进行基因诊断的直接测序替代方法。我们在两个家族的先证者中均鉴定出第10外显子密码子618(C618R)的种系错义突变T→C。通过使用ARMS,还发现MEN2A家族的两名成员和FMTC家族的五名成员C618R突变呈阳性。这是塞浦路斯首批在临床和分子层面进行详细研究且被证明传递这种常见RET原癌基因突变的看似无血缘关系的家族。